Literature DB >> 19104837

Integrin beta3 down-regulates invasive features of ovarian cancer cells in SKOV3 cell subclones.

Jie Chen1, Jie Zhang, Yaoran Zhao, Jun Li, Maosun Fu.   

Abstract

PURPOSE: To investigate the role of integrin beta3 in invasive features of ovarian cancer SKOV3 cells, by comparing different metastatic subclones.
METHODS: In the present study, two cell subclones, termed as S1 and S21, which possessed high and low metastatic potential, respectively, were isolated and established from human ovarian cancer parental cell line SKOV3 by the limited dilution method. The expressions of integrin alphav, integrin alphavbeta3, integrin beta3, E-cadherin, FAK and ILK in the two cell subclones were compared by means of real-time RT-PCR or flow cytometry. Subsequently, S21 was transfected with siRNA for integrin beta3 and the effects of transfection were examined by methyl thiazolyl tetrazolium (MTT) assay, colony formation assay, Matrigel invasion assay and cell migration assay.
RESULTS: The expressions of integrin alphavbeta3, integrin beta3 and E-cadherin were markedly down-regulated in S1; however, there were no significant differences in the expressions of integrin alphav, FAK and ILK beta. Of note, more than 70% knockdown of integrin beta3 expression was obtained by siRNA technique. The integrin beta3-siRNA-transfected cells showed significant increases in cell proliferation, cell migration and invasive activity in contrast with the mock-transfected cells. The expressions of integrin alphavbeta3 and E-cadherin were lower in the integrin beta3-siRNA-transfected cells compared to the mock control.
CONCLUSION: Integrin beta3, like E-cadherin, may be also a suppressor gene down-regulating invasive features of ovarian cancer cells in SKOV3 cell subclones.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19104837     DOI: 10.1007/s00432-008-0526-8

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  48 in total

1.  Increased risk of ovarian cancer in integrin beta3 Leu33Pro homozygotes.

Authors:  S E Bojesen; S K Kjaer; E V S Høgdall; B L Thomsen; C K Høgdall; J Blaakaer; A Tybjaerg-Hansen; B G Nordestgaard
Journal:  Endocr Relat Cancer       Date:  2005-12       Impact factor: 5.678

Review 2.  Integrin-regulated FAK-Src signaling in normal and cancer cells.

Authors:  Satyajit K Mitra; David D Schlaepfer
Journal:  Curr Opin Cell Biol       Date:  2006-08-17       Impact factor: 8.382

3.  Genetic variation in platelet integrin alphabeta (GPIIb/IIIa) and the metastatic potential of renal cell carcinoma.

Authors:  Jukka P Kallio; Jussi Mikkelsson; Teuvo L J Tammela; Pekka J Karhunen; Pirkko Kellokumpu-Lehtinen
Journal:  BJU Int       Date:  2006-07       Impact factor: 5.588

4.  Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture.

Authors:  I J Fidler
Journal:  Cancer Res       Date:  1990-10-01       Impact factor: 12.701

5.  Establishment of a hepatocellular carcinoma cell line with unique metastatic characteristics through in vivo selection and screening for metastasis-related genes through cDNA microarray.

Authors:  Y Li; Y Tang; L Ye; B Liu; K Liu; J Chen; Q Xue
Journal:  J Cancer Res Clin Oncol       Date:  2002-12-04       Impact factor: 4.553

Review 6.  Inhibitors of integrins.

Authors:  Gordon C Tucker
Journal:  Curr Opin Pharmacol       Date:  2002-08       Impact factor: 5.547

Review 7.  The integrin-extracellular matrix axis in pancreatic cancer.

Authors:  John J Grzesiak; Jason C Ho; Abdool R Moossa; Michael Bouvet
Journal:  Pancreas       Date:  2007-11       Impact factor: 3.327

8.  Expression level of the nm23 gene in clonal populations of metastatic murine and human neoplasms.

Authors:  R Radinsky; H Z Weisberg; A N Staroselsky; I J Fidler
Journal:  Cancer Res       Date:  1992-10-15       Impact factor: 12.701

9.  Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion.

Authors:  Anil K Sood; Jeremy E Coffin; Galen B Schneider; Mavis S Fletcher; Barry R DeYoung; Lynn M Gruman; David M Gershenson; Michael D Schaller; Mary J C Hendrix
Journal:  Am J Pathol       Date:  2004-10       Impact factor: 4.307

Review 10.  Integrins: a method of early intervention in the treatment of colorectal liver metastases.

Authors:  John H Robertson; Arthur M Iga; Kevin M Sales; Marc C Winslet; Alexander M Seifalian
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

View more
  15 in total

1.  Proteomics identification of ITGB3 as a key regulator in reactive oxygen species-induced migration and invasion of colorectal cancer cells.

Authors:  Yunlong Lei; Kai Huang; Cong Gao; Quek Choon Lau; Hua Pan; Ke Xie; Jingyi Li; Rui Liu; Tao Zhang; Na Xie; Huey Shan Nai; Hong Wu; Qiang Dong; Xia Zhao; Edouard C Nice; Canhua Huang; Yuquan Wei
Journal:  Mol Cell Proteomics       Date:  2011-05-27       Impact factor: 5.911

2.  ß3 integrin modulates transforming growth factor beta induced (TGFBI) function and paclitaxel response in ovarian cancer cells.

Authors:  David A Tumbarello; Jillian Temple; James D Brenton
Journal:  Mol Cancer       Date:  2012-05-28       Impact factor: 27.401

3.  SPARC is a key regulator of proliferation, apoptosis and invasion in human ovarian cancer.

Authors:  Jie Chen; Mei Wang; Bo Xi; Jian Xue; Dan He; Jie Zhang; Yueran Zhao
Journal:  PLoS One       Date:  2012-08-03       Impact factor: 3.240

4.  Fibulin-4 is associated with tumor progression and a poor prognosis in ovarian carcinomas.

Authors:  Jie Chen; Zhao Liu; Shuang Fang; Rui Fang; Xi Liu; Yueran Zhao; XiangXin Li; Lei Huang; Jie Zhang
Journal:  BMC Cancer       Date:  2015-03-04       Impact factor: 4.430

5.  The H3K9 methyltransferase G9a is a marker of aggressive ovarian cancer that promotes peritoneal metastasis.

Authors:  Kuo-Tai Hua; Ming-Yang Wang; Min-Wei Chen; Lin-Hung Wei; Chi-Kuan Chen; Ching-Huai Ko; Yung-Ming Jeng; Pi-Lin Sung; Yi-Hua Jan; Michael Hsiao; Min-Liang Kuo; Men-Luh Yen
Journal:  Mol Cancer       Date:  2014-08-12       Impact factor: 27.401

6.  Cancer stem cell marker CD90 inhibits ovarian cancer formation via β3 integrin.

Authors:  Wei-Ching Chen; Hui-Ping Hsu; Chung-Yen Li; Ya-Ju Yang; Yu-Hsuan Hung; Chien-Yu Cho; Chih-Yang Wang; Tzu-Yang Weng; Ming-Derg Lai
Journal:  Int J Oncol       Date:  2016-09-15       Impact factor: 5.650

7.  Inhibition of integrin β3, a binding partner of kallistatin, leads to reduced viability, invasion and proliferation in NCI-H446 cells.

Authors:  Guoquan Wang; Xiao Wang; Xiaoping Huang; Huiyong Yang; Suqiu Pang; Xiaolan Xie; Shulan Zeng; Junsheng Lin; Yong Diao
Journal:  Cancer Cell Int       Date:  2016-12-01       Impact factor: 5.722

8.  Overexpression of EFEMP1 correlates with tumor progression and poor prognosis in human ovarian carcinoma.

Authors:  Jie Chen; Deying Wei; Yueran Zhao; Xiaoyan Liu; Jie Zhang
Journal:  PLoS One       Date:  2013-11-13       Impact factor: 3.240

9.  The PI3K/AKT/mTOR pathway is a potential predictor of distinct invasive and migratory capacities in human ovarian cancer cell lines.

Authors:  Huimin Bai; Haixia Li; Weihua Li; Ting Gui; Jiaxin Yang; Dongyan Cao; Keng Shen
Journal:  Oncotarget       Date:  2015-09-22

10.  Integrin-linked kinase activity modulates the pro-metastatic behavior of ovarian cancer cells.

Authors:  Lana Bruney; Yueying Liu; Anne Grisoli; Matthew J Ravosa; M Sharon Stack
Journal:  Oncotarget       Date:  2016-04-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.